Beyond Cancer: How Immunopeptidomics is Unlocking the Next Frontier in HIV Cure Research

Can we cure HIV?

For decades, the answer has been a cautious “not yet.” But on January 31, 2026, a groundbreaking study published in Nature Communications signaled a massive shift in the armamentarium of infectious disease specialists.

By leveraging an engineered T Cell Receptor (TCR) targeting a specific HIV peptide, researchers from Immunocore have demonstrated a successful “proof of concept” that immunotherapy—once the crown jewel of oncology—is officially ready to tackle the world’s most persistent viral reservoirs.

At Alithea Bio, we believe this milestone underscores the critical role of immunopeptidomics and precision medicine in solving the most complex challenges in human health

The Science: IMC-M113V and the HLA-A*02:01 Target
The challenge with HIV isn’t just the virus itself; it’s the “reservoir.” Even with suppressive Antiretroviral Therapy (ART), the virus hides in a latent state within the body. To eliminate it, we need a way to “see” the infected cells.

This is where immunopeptidomics becomes the hero of the story. The IMC-M113V-103 study
utilized IMC-M113V, a bispecific TCR designed to:
Recognize a specific viral peptide (Gag77-85).
Bind to that peptide when presented by the HLA-A*02:01 molecule.
Redirect the body’s own T cells to kill the infected cell, even when viral copy numbers are extremely low.
Why This Matters for Precision Medicine
This study is a masterclass in precision. The therapy didn’t just target HIV generally; it targeted a specific immunopeptidome profile. The results showed that pharmacodynamic (PD) activity was strongest in participants whose viral sequences were most sensitive to the IMC-M113V TCR.
This confirms what we advocate for at Alithea Bio: The future of medicine is not “one size fits all.” It is molecularly targeted.

Breaking the “Cancer-Only” Mold
For years, bispecific TCRs and T-cell redirecting therapies were viewed primarily as cancer treatments. This first-in-human trial proves that the same logic can be applied to chronic viral infections.
In an era where viral threats are evolving and pathogens are becoming increasingly resistant to traditional antibiotics, we must look toward the immune system for the next generation of “living drugs.”
Key Takeaways from the Study:
Safety First: The trial was a single ascending dose study in twelve males living with HIV. IMC-M113V was well-tolerated with no serious adverse events.
Dose-Dependent Results: The activity of the drug scaled with the dosage, providing a clear roadmap for future higher-dose trials.
The Power of the Peptide: The success of the treatment relied entirely on the correct identification and targeting of the HIV Gag peptide.

The Alithea Bio Perspective: Powering the Discovery
At Alithea Bio, we are inspired by these advancements. Our focus on immunopeptidomics and high-resolution HLA typing is exactly what enables researchers to find these “needles in the haystack”—the specific peptides like Gag77-85 that make targeted therapy possible.
As we move toward a world of ART-free virological control, the ability to map the landscape of cellular presentation is the key that will unlock the cure.

🌐 Join the Conversation
Is immunotherapy the final step in the journey toward an HIV cure? How will immunopeptidomics reshape our approach to infectious diseases?
Explore Alithea Bio’s Immunopeptidomics Services | Contact our Precision Medicine Team